AC
ALXN

Apogem Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Apogem Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,500
Closed -$391K – 227
2020
Q4 		$391K Buy
+2,500
New +$321K 0.26% 115

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apogem Capital's ALXN Position: Q1 2021 in Review

Apogem Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 10,830 shares — an estimated $1.69M sold.

Apogem Capital first reported a position in ALXN in Q4 2020 and held it in 1 quarter. The position peaked at $1.69M in Q4 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Apogem Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Apogem Capital sold 10,830 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.69M.
  • Apogem Capital first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Apogem Capital's Alexion Pharmaceuticals position peaked at $1.69M in Q4 2020.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Apogem Capital's 13F filing for Q1 2021, filed 14 May 2021.